Inhibrx, Inc.

NASDAQ:INBX

14.6 (USD) • At close December 20, 2024
Bedrijfsnaam Inhibrx, Inc.
Symbool INBX
Munteenheid USD
Prijs 14.6
Beurswaarde 211,348,198
Dividendpercentage 0%
52-weken bereik 10.8 - 18.95
Industrie Biotechnology
Sector Healthcare
CEO Mr. Mark Paul Lappe
Website https://inhibrx.com

An error occurred while fetching data.

Over Inhibrx, Inc.

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional

Vergelijkbare Aandelen

Cullinan Oncology, Inc. logo

Cullinan Oncology, Inc.

CGEM

11.6 USD

Intercept Pharmaceuticals, Inc. logo

Intercept Pharmaceuticals, Inc.

ICPT

19 USD

Nano-X Imaging Ltd. logo

Nano-X Imaging Ltd.

NNOX

6.76 USD

ANI Pharmaceuticals, Inc. logo

ANI Pharmaceuticals, Inc.

ANIP

53.35 USD

Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc.

CRBU

1.8 USD

Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC

1.1 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)